What is Cerus?
Headquartered in Concord, California, Cerus is dedicated to enhancing blood safety through its innovative INTERCEPT Blood System. This technology is designed to inactivate a broad spectrum of viruses, bacteria, and parasites present in blood components, including platelets and plasma, with ongoing programs extending to red blood cells. By providing a robust solution for pathogen reduction, Cerus addresses a critical need for blood centers and hospitals worldwide, aiming to minimize transfusion-transmitted infections and improve patient outcomes. The company's commitment to advancing transfusion medicine positions it as a key player in the healthcare technology sector.
How much funding has Cerus raised?
Cerus has raised a total of $268.6M across 7 funding rounds:
Stock Offering
$21.3M
Debt
$10M
Debt
$30M
Debt
$40M
Debt
$90M
Stock Offering
$63.3M
Unspecified
$14M
Stock Issuance/Offering (1997): $21.3M with participation from Undisclosed
Debt (2010): $10M led by Oxford Finance Corporation
Debt (2014): $30M supported by Oxford Finance
Debt (2017): $40M featuring Oxford Finance Corporation
Debt (2019): $90M backed by MidCap Financial
Stock Issuance/Offering (2020): $63.3M with participation from Undisclosed
Unspecified (2020): $14M led by Biomedical Advanced Research and Development Authority
Key Investors in Cerus
MidCap Financial
MidCap Financial is a specialty finance firm known for providing flexible and efficient financing solutions, particularly for companies seeking to accelerate their growth and operational capabilities.
Oxford Finance Corporation
Oxford Finance Corporation is a specialty finance firm established in 2002, offering tailored financial solutions to companies within the healthcare and life sciences industries globally.
Biomedical Advanced Research and Development Authority
The Biomedical Advanced Research and Development Authority (BARDA) is a U.S. government agency focused on supporting the development of medical countermeasures against public health threats.
What's next for Cerus?
With the recent infusion of $14M in a major strategic investment, Cerus is poised for significant expansion. This capital injection, part of its overall $268.6M in funding, will likely accelerate the adoption of its INTERCEPT Blood System across global markets. The company's focus on developing advanced pathogen-reduction technologies for platelets, plasma, and red blood cells indicates a strategic roadmap aimed at broadening its product portfolio and market reach. Future endeavors may include further clinical validation, regulatory approvals in new territories, and scaling manufacturing capabilities to meet increasing demand. Cerus's trajectory suggests a continued emphasis on innovation and strategic partnerships to solidify its leadership in blood safety solutions.
See full Cerus company page
